Editorial for effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis

Journal of Cystic Fibrosis

Volumn 11, Issue 2, 2012, Pages 77-

  Tiddens, Harm A W M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DORNASE ALFA;

CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG EFFICACY; EARLY INTERVENTION; EDITORIAL; EVIDENCE BASED MEDICINE; FORCED VITAL CAPACITY; HUMAN; INFLAMMATION; LUNG FUNCTION; ORGAN PRESERVATION; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; SURVIVAL;

CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; HUMANS;

EID: 84858166422     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.03.001     Document Type: Editorial

References (3)

1. Konstan M.W., Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 2012, e-pub 2011/11/19.
2. Bakker E.M., Tiddens H.A. Phamacology, clinical efficacy and safety of recombinant human DNase in cystic fibrosis. Expert Rev Resp Med 2007, 1(3):317-329.
3. Quan J.M., Tiddens H.A., et al. A two-year randomized, placebo controlled trial of dornase alfa in young cystic fibrosis patients with mild lung function abnormalities. J Pediatr 2001, 139:813-820.